[{"address1": "41 South Rio Grande Street", "city": "Salt Lake City", "state": "UT", "zip": "84101", "country": "United States", "phone": "385 269 0203", "fax": "801 821 2872", "website": "https://www.recursion.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 800, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher C. Gibson Ph.D.", "age": 41, "title": "Co-Founder, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 806716, "exercisedValue": 2177540, "unexercisedValue": 222044}, {"maxAge": 1, "name": "Dr. Dean Y. Li M.D., Ph.D.", "age": 60, "title": "Co-Founder & Independent Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 47505, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Blake C. Borgeson Ph.D.", "age": 42, "title": "Co-Founder & Director", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 40000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David J. Mauro M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 674737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben R. Taylor", "age": 47, "title": "CFO & President of Recursion UK", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen  Rushton M.B.A.", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kevin  Leggat", "title": "Vice President of Finance & Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Mabey M.S.", "age": 41, "title": "Chief Technology Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Hallett Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erica  Fox", "title": "Chief People and Impact Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.24, "open": 6.2, "dayLow": 6.15, "dayHigh": 6.642, "regularMarketPreviousClose": 6.24, "regularMarketOpen": 6.2, "regularMarketDayLow": 6.15, "regularMarketDayHigh": 6.642, "payoutRatio": 0.0, "beta": 0.845, "forwardPE": -3.8092487, "volume": 19102954, "regularMarketVolume": 19102954, "averageVolume": 23494132, "averageVolume10days": 26854170, "averageDailyVolume10Day": 26854170, "bid": 6.57, "ask": 6.62, "bidSize": 153, "askSize": 151, "marketCap": 2649120768, "fiftyTwoWeekLow": 5.6, "fiftyTwoWeekHigh": 12.36, "priceToSalesTrailing12Months": 45.023212, "fiftyDayAverage": 7.5898, "twoHundredDayAverage": 7.395675, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2163260416, "profitMargins": 0.0, "floatShares": 382618739, "sharesOutstanding": 395072000, "sharesShort": 75450107, "sharesShortPriorMonth": 67857806, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.1877, "heldPercentInsiders": 0.03619, "heldPercentInstitutions": 0.76989, "shortRatio": 3.06, "shortPercentOfFloat": 0.2041, "impliedSharesOutstanding": 401991008, "bookValue": 2.608, "priceToBook": 2.5268404, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -463660992, "trailingEps": -1.69, "forwardEps": -1.73, "enterpriseToRevenue": 36.766, "enterpriseToEbitda": -4.889, "52WeekChange": -0.39826423, "SandP52WeekChange": 0.121255875, "quoteType": "EQUITY", "currentPrice": 6.59, "targetHighPrice": 11.0, "targetLowPrice": 6.0, "targetMeanPrice": 9.0, "targetMedianPrice": 10.0, "recommendationMean": 2.625, "recommendationKey": "hold", "numberOfAnalystOpinions": 7, "totalCash": 594350016, "totalCashPerShare": 1.479, "ebitda": -442510016, "totalDebt": 108492000, "quickRatio": 3.433, "currentRatio": 3.81, "totalRevenue": 58839000, "debtToEquity": 10.485, "revenuePerShare": 0.215, "returnOnAssets": -0.28481, "returnOnEquity": -0.61895, "grossProfits": -300820000, "freeCashflow": -194332000, "operatingCashflow": -359174016, "revenueGrowth": -0.583, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -40.447872, "financialCurrency": "USD", "symbol": "RXRX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Recursion Pharmaceuticals, Inc.", "longName": "Recursion Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "epsTrailingTwelveMonths": -1.69, "epsForward": -1.73, "epsCurrentYear": -1.64009, "priceEpsCurrentYear": -4.018072, "fiftyDayAverageChange": -0.9997997, "fiftyDayAverageChangePercent": -0.1317294, "twoHundredDayAverageChange": -0.805675, "twoHundredDayAverageChangePercent": -0.10893867, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-04-16", "averageAnalystRating": "2.6 - Hold", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1741395578, "regularMarketTime": 1741381201, "exchange": "NMS", "messageBoardId": "finmb_261401243", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 5.6089807, "regularMarketPrice": 6.59, "marketState": "CLOSED", "firstTradeDateMilliseconds": 1618579800000, "postMarketChangePercent": 0.151741, "postMarketPrice": 6.6, "postMarketChange": 0.00999975, "regularMarketChange": 0.35000038, "regularMarketDayRange": "6.15 - 6.642", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 23494132, "fiftyTwoWeekLowChange": 0.99000025, "fiftyTwoWeekLowChangePercent": 0.17678577, "fiftyTwoWeekRange": "5.6 - 12.36", "fiftyTwoWeekHighChange": -5.7699995, "fiftyTwoWeekHighChangePercent": -0.46682847, "fiftyTwoWeekChangePercent": -39.826424, "earningsTimestamp": 1740749400, "earningsTimestampStart": 1746648000, "earningsTimestampEnd": 1747080000, "earningsCallTimestampStart": 1740749400, "earningsCallTimestampEnd": 1740749400, "isEarningsDateEstimate": true, "displayName": "Recursion Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]